As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
• PPB(plasma protein-binding):3 concentrations (including effective concentrations),N=3, focusing on concentration dependence and species differences.
• Metabolic stability/MetID (in vitro metabolism): Metabolic stability/ METID (in vitro metabolism): Focuses on species differences to provide a reference for PK/PD/Tox species selection in vivo
• CYP inhibition (P450p system): IC50 or Ki, 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4
• CYP induction (P450 induction): human hepatocytes from 3 donors, mRNA expression and/or enzyme activity changes:1A2, 2B6, 3A4 (refer to FDA Guidances: DD2006 Draft and 2020 In vitro DDI for data analysis)
• Reaction phenotyping: Identification of CYP/Non-CYP metabolic pathways
• Caco-2: In vitro absorption model
• Transporter substrate assessment & inhibition (Transporter study):
(1) P-gp, BCRP
(2) Liver transporters (OATP1B1, OATP1B3)
(3) Kidney transporters (OAT1, POAT3, OCT2, MATE1, MATE2-K)